stonks4u
Sign up free
JAZZ logo

JAZZ Jazz Pharmaceuticals plc

NASDAQ · Biotechnology · Healthcare

$244.96
-0.89 (-0.36%)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC);…

Market Cap: $15.39Bwww.jazzpharma.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

57
5788119150
Aug 10Aug 12

Quote

Day Range
$240.63 – $245.25
52-Week Range
$117.10 – $265.05
Volume
$535.5K
Market Cap
$15.39B
50-Day Avg
$243.01
200-Day Avg
$197.19
Prev Close
$245.85
Open
$243.59

Valuation & Ratios

P/E Ratio
-29.11
EPS
$-5.84
P/B Ratio
2.40
P/S Ratio
2.43
Debt/Equity
1.26
Current Ratio
1.86
Dividend Yield
+0.0%
Gross Margin
+88.2%

Returns & Efficiency

Return on Equity
-8.2%
Return on Assets
-3.1%
FCF Yield
+11.1%
EV/EBITDA
132.76

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$4.27B$-356.15M$-5.84
2024$4.07B$560.12M$9.06
2023$3.83B$414.83M$6.55
2022$3.66B$-224.06M$-3.58
2021$3.09B$-328.95M$-5.51

Social Signal Score

54
5d
57
1 mentions
—
30d
53
3 mentions
—
60d
53
3 mentions
—
90d
53
3 mentions
—
news: 3

Earnings

Wed, Nov 4(in 3 months)

Consensus estimate $6.49 per share

4of 7 quarters beat consensus

Typical surprise +1.8% (median, so one quarter with a near-zero estimate can't distort it)

  • Mon, Aug 3$5.71 vs $6.18miss
  • Tue, May 5$6.34 vs $4.64beat
  • Tue, Feb 24$6.64 vs $6.52beat
  • Wed, Nov 5$8.13 vs $5.95beat
  • Tue, Aug 5$-8.25 vs $-6.12miss
  • Tue, May 6$1.68 vs $4.51miss

Estimates and results for JAZZ via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

JAZZhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (3)

  • Newsseekingalpha.com·3d ago·Neutral

    Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout Jazz Pharmaceuticals acquires Actio Biosciences for $820 million upfront, targeting rare KCNT1+ epilepsy with ABS-1230, a registrational-stage precision therapy. JAZZ delivered record Q2 2026 revenues of ~$1.2 billion, with strong year-on-year growth in key assets like Xywav (+13%) and Zepzelca (+42%). Despite a competitive narcolepsy landscape and $4.4 billion in debt, JAZZ's diversified portfolio, robust cash positio

    View source ↗
  • Newsreuters.com·5d ago·Positive

    Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio Jazz Pharmaceuticals said on Monday it would buy privately held Actio Biosciences in a deal valued at ​up to $1.32 billion, adding an experimental treatment for ‌a rare inherited form of epilepsy that has no approved therapies.

    View source ↗
  • Newsprnewswire.com·5d ago·Negative

    Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction includes $820 million upfront payment  DUBLIN and SAN DIEGO, Aug. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have en

    View source ↗